USPH Stock Analysis: U.S. Physical Therapy | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 1.253m USD | 12M Return: -2.3% | US90337L1089 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.0M
EPS Trend: 21.8%
Qual. Beats: -1
Rev. Trend: 93.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
U.S. Physical Therapy, Inc. (NYSE: USPH) operates and manages outpatient physical therapy clinics through two segments: Physical Therapy Operations and Industrial Injury Prevention Services. The company delivers pre- and post-operative orthopedic care, sports injury treatment, neurological rehabilitation, and workers compensation rehabilitation. Its Industrial Injury Prevention Services segment provides onsite injury prevention, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments-primarily serving Fortune 500 employers as well as insurers and their contractors. Founded in 1990 and headquartered in Houston, Texas, USPH operates within the healthcare facilities sub-industry and runs a clinic-partner model in which licensed therapists often hold equity stakes in individual clinics, aligning clinician incentives with site performance-a structure common among large U.S. outpatient therapy operators.
- Patient visit volumes and same-store growth drive clinic segment revenue
- Industrial Injury Prevention Services expands with Fortune 500 contracts
- Therapist wage inflation pressures operating margins across clinic network
| Net Income: -6.03m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.03 > 1.0 |
| NWC/Revenue: 3.82% < 20% (prev 3.26%; Δ 0.56% < -1%) |
| CFO/TA 0.07 > 3% & CFO 83.0m > Net Income -6.03m |
| Net Debt (526.7m) to EBITDA (100.3m): 5.25 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.1m) vs 12m ago -0.84% < -2% |
| Gross Margin: 19.17% > 18% (prev 20.37%; Δ -1.20% > 0.5%) |
| Asset Turnover: 64.16% > 50% (prev 56.39%; Δ 7.77% > 0%) |
| Interest Coverage Ratio: 7.27 > 6 (EBIT TTM 78.2m / Interest Expense TTM 10.8m) |
| A: 0.02 (Total Current Assets 139.7m - Total Current Liabilities 109.9m) / Total Assets 1.25b |
| B: 0.17 (Retained Earnings 213.4m / Total Assets 1.25b) |
| C: 0.06 (EBIT TTM 78.2m / Avg Total Assets 1.21b) |
| D: 0.93 (Book Value of Equity 448.7m / Total Liabilities 482.2m) |
| Altman-Z'' = 2.12 = BBB |
| DSRI: 0.90 (Receivables 98.2m/93.4m, Revenue 779.1m/665.2m) |
| GMI: 1.06 (GM 20.37% / 19.17%) |
| AQI: 0.89 (AQ_t 0.66 / AQ_t-1 0.74) |
| SGI: 1.17 (Revenue 779.1m / 665.2m) |
| TATA: -0.07 (NI -6.03m - CFO 83.0m) / TA 1.25b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at USD 84.67 with a total of 143,458 shares traded. Over the past week, the price has changed by +1.13%, over one month by +8.73%, over three months by +15.96% and over the past year by -2.26%.
Current recommended Stop Loss: 81.70 (which is 3.5% or 1.3 ATR below the current price).
U.S. Physical Therapy has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy USPH.
- StrongBuy: 2
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 97 | 14.6% |
P/E Trailing = 466.4444
P/E Forward = 27.248
P/S = 1.5578
P/B = 2.7663
P/EG = 2.7269
Revenue TTM = 779.1m USD
EBIT TTM = 78.2m USD
EBITDA TTM = 100.3m USD
Long Term Debt = 215.5m USD (from longTermDebt, last quarter)
Short Term Debt = 47.4m USD (from shortTermDebt, last quarter)
Debt = 551.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 165.8m
Net Debt = 526.7m USD (calculated: Debt 551.6m - CCE 24.9m)
Enterprise Value = 1.78b USD (1.25b + Debt 551.6m - CCE 24.9m)
Interest Coverage Ratio = 7.27 (Ebit TTM 78.2m / Interest Expense TTM 10.8m)
EV/FCF = 27.77x (Enterprise Value 1.78b / FCF TTM 64.1m)
FCF Yield = 3.60% (FCF TTM 64.1m / Enterprise Value 1.78b)
FCF Margin = 8.22% (FCF TTM 64.1m / Revenue TTM 779.1m)
Net Margin = -0.77% (Net Income TTM -6.03m / Revenue TTM 779.1m)
Gross Margin = 19.17% ((Revenue TTM 779.1m - Cost of Revenue TTM 629.7m) / Revenue TTM)
Gross Margin QoQ = 19.59% (prev 14.47%)
Tobins Q-Ratio = 1.42 (Enterprise Value 1.78b / Total Assets 1.25b)
Interest Expense / Debt = 1.95% (Interest Expense 10.8m / Debt 551.6m)
Taxrate = 26.06% (17.6m / 67.4m)
NOPAT = 57.8m (EBIT 78.2m * (1 - 26.06%))
Current Ratio = 1.27 (Total Current Assets 139.7m / Total Current Liabilities 109.9m)
Debt / Equity = 1.23 (Debt 551.6m / totalStockholderEquity, last quarter 448.7m)
Debt / EBITDA = 5.25 (Net Debt 526.7m / EBITDA 100.3m)
Debt / FCF = 8.22 (Net Debt 526.7m / FCF TTM 64.1m)
Total Stockholder Equity = 474.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.50% (Net Income -6.03m / Total Assets 1.25b)
RoE = -1.27% (Net Income TTM -6.03m / Total Stockholder Equity 474.4m)
RoCE = 11.34% (EBIT 78.2m / Capital Employed (Equity 474.4m + L.T.Debt 215.5m))
RoIC = 4.98% (NOPAT 57.8m / Invested Capital 1.16b)
WACC = 6.25% (E(1.25b)/V(1.80b) * Re(8.36%) + D(551.6m)/V(1.80b) * Rd(1.95%) * (1-Tc(0.26)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 59.24 | Cagr: 0.16%
[DCF] Terminal Value 76.11% ; FCFF base≈62.8m ; Y1≈65.8m ; Y5≈75.9m
[DCF] Fair Price = 43.13 (EV 1.17b - Net Debt 526.7m = Equity 643.7m / Shares 14.9m; r=8.35% [WACC [floored]]; 5y FCF grow 5.26% → 2.50% )
EPS Correlation: 21.82 | EPS CAGR: 0.64% | SUE: -1.10 | # QB: -1
Revenue Correlation: 93.85 | Revenue CAGR: 8.51% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.73 | Chg30d=-4.71% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=2.90 | Chg30d=+0.15% | Revisions=+25% | GrowthEPS=+10.2% | GrowthRev=+8.6%
EPS next Year (2027-12-31): EPS=3.35 | Chg30d=-2.65% | Revisions=+0% | GrowthEPS=+15.6% | GrowthRev=+7.6%
[Analyst] Revisions Ratio: +12% (up=3, down=2)